Standard Life Aberdeen (LON:SLA) Price Target Increased to GBX 225 by Analysts at Royal Bank of Canada

Share on StockTwits

Standard Life Aberdeen (LON:SLA) had its price target increased by analysts at Royal Bank of Canada from GBX 220 ($2.71) to GBX 225 ($2.77) in a research report issued to clients and investors on Wednesday, ThisIsMoney.Co.Uk reports. The brokerage currently has an “underperform” rating on the stock. Royal Bank of Canada’s price target points to a potential downside of 15.92% from the company’s previous close.

A number of other analysts have also recently weighed in on SLA. Morgan Stanley upped their target price on shares of Standard Life Aberdeen from GBX 195 ($2.40) to GBX 230 ($2.83) and gave the company an “underweight” rating in a research note on Wednesday, June 3rd. Deutsche Bank reiterated a “hold” rating on shares of Standard Life Aberdeen in a research note on Monday, June 22nd. Credit Suisse Group raised their price target on shares of Standard Life Aberdeen from GBX 210 ($2.58) to GBX 240 ($2.95) and gave the company an “underperform” rating in a report on Thursday, June 25th. UBS Group raised their price target on shares of Standard Life Aberdeen from GBX 185 ($2.28) to GBX 255 ($3.14) and gave the company a “neutral” rating in a report on Thursday, June 18th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Standard Life Aberdeen in a report on Tuesday, June 16th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of GBX 238 ($2.93).

LON SLA opened at GBX 267.60 ($3.29) on Wednesday. The company has a market cap of $5.99 billion and a P/E ratio of 24.11. The company has a fifty day simple moving average of GBX 249.57 and a 200 day simple moving average of GBX 267.15. The company has a current ratio of 2.66, a quick ratio of 1.18 and a debt-to-equity ratio of 18.92. Standard Life Aberdeen has a 1 year low of GBX 170.30 ($2.10) and a 1 year high of GBX 338.25 ($4.16).

In other news, insider Keith Skeoch purchased 658 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was bought at an average cost of GBX 230 ($2.83) per share, for a total transaction of £1,513.40 ($1,862.42). Insiders have bought 761 shares of company stock valued at $176,230 over the last quarter.

About Standard Life Aberdeen

Standard Life Aberdeen plc provides asset management services in the United Kingdom, Europe, North America, and Asia. The company offers investment solutions and funds; long-term savings and investment products to individual and corporate customers; and life insurance and savings products. It provides its products through institutional, wholesale, and retail distribution channels.

Further Reading: Is it better to buy a fund with a higher or lower NAV?

Analyst Recommendations for Standard Life Aberdeen (LON:SLA)

Receive News & Ratings for Standard Life Aberdeen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard Life Aberdeen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Greenhill & Co., Inc.  Shares Sold by State of Tennessee Treasury Department
Greenhill & Co., Inc. Shares Sold by State of Tennessee Treasury Department
Geode Capital Management LLC Has $3.26 Million Stock Position in Cytosorbents Corp
Geode Capital Management LLC Has $3.26 Million Stock Position in Cytosorbents Corp
Invesco Ltd. Acquires Shares of 372,672 Kala Pharmaceuticals Inc
Invesco Ltd. Acquires Shares of 372,672 Kala Pharmaceuticals Inc
Northern Technologies International  Downgraded by Zacks Investment Research
Northern Technologies International Downgraded by Zacks Investment Research
MaxLinear  Rating Increased to Buy at Zacks Investment Research
MaxLinear Rating Increased to Buy at Zacks Investment Research
Zacks Investment Research Downgrades Obic  to Sell
Zacks Investment Research Downgrades Obic to Sell


© 2006-2020 Ticker Report